SOUTHAMPTON babies are set to play a vital role in a new study on contagious breathing infections.

University Hospital Southampton is leading the research study combatting the main cause of infant hospitalisation due to a contagious breathing infection.

Respiratory Syncytial Virus (RSV) affects 90 per cent of children before the age of two.

In recent months, there has been a resurgence of the virus following the easing of Covid public health measures.

The HARMONIE study will be carried out a UHS and is a collaboration between Sanofi and the National Institute for Health and Care Research (NIHR).

It aims to measure the efficacy of a drug called nirsevimab, a monoclonal antibody immunisation.

The research will include newborn babies up to the age of 12 months old who are in, or are approaching, their first RSV season.

More than 20,000 babies across the UK, Germany and France will take part in the March 2023 study.

Dr Katrina Cathie, UHS consultant paediatrician and Southampton study lead, said: “RSV infection is very common and every year our wards are full of babies with breathing and feeding problems, with some becoming very unwell. It is exciting to know there is an antibody treatment that could protect babies in the near future.

“The HARMONIE study is vital to assess the impact on hospitalisations due to RSV and we are asking all parents of babies under one year to consider taking part.

"There is a single study visit, no blood tests and further details are collected remotely via an app at intervals over a year.”

In most cases RSV will cause only mild illnesses, with cold symptoms like a runny nose, coughing and sneezing. However, for some babies, it leads to more severe lung problems such as bronchiolitis and pneumonia.

Nearly 80 per cent of the children admitted to hospital with RSV are previously healthy.

Professor Andrew Ustianowski, National Specialty Lead for Infection at NIHR Clinical Research Network, said: “This study, supported by the NIHR across more than 100 sites, provides the UK with the opportunity to lead the way in a disease which impacts infants globally.

“By carrying out this widespread study, we can help discover how babies can be protected from such a common, yet potentially debilitating virus.

"Previous smaller studies of the antibody injection being used has shown nirsevimab has a good safety profile in babies, which will hopefully provide parents with confidence to take part in the study.”

Dr Bogdana Coudsy, Global Head of Medical for Vaccines at Sanofi, said: “Given RSV is a leading cause of hospitalisation in all infants, we are excited to start this research that puts the needs of participants, carers, and investigators at the heart of its development.

"This is an innovative study in design and execution, a model for the future, thanks to a hybrid digital design and close collaborative work.”

A message from the Editor

Thank you for reading this article - we appreciate your support in reading the Daily Echo.

Subscribing to the Echo means you have unrestricted access to the latest news, features and Saints coverage - all with an advertising-light website.

You will also have full access to Saintsplus, your new home for Southampton FC tactical analysis, features and much, much more.

Don't just take my word for it - subscribe today.

Follow the latest breaking news in the Southampton area by searching Southampton News - Breaking News and Incidents on Facebook

Follow the latest court and crime news on our dedicated group by searching Hampshire Court and Crime News on Facebook